fda and glp-1 Safety Check FDA Approves Oral Semaglutide as

at 52 Weeks MariTide Delivered Substantial Improvements Across Cardiometabolic Parameters Announces "MARITIME," a Phase 3 Clinical Development Program in Obesity and Obesity-Related Conditions 1 The study also showed people living with obesity or overweight and Type 2 diabetes, who typically lose less weight on GLP-1 therapies, achieved up to ~17% average weight loss, also without a weight loss plateau, and lowered their average hemoglobin A1C (HbA1c) by up to 2.2 percentage points at week 52

2008;3(9):e3163

ColonBroom includes 15 mg of zinc citrate, contributing a significant portion of daily needs and supporting both metabolic and immune health

doi: 10.1038/s41598-022-05323-7

So just keep that in mind that these studies didnt necessarily calculate whether these adverse reactions were statistically significant